Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Palbociclib and Pembrolizumab in Central Nervous System Metastases

NCT02896335 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02896335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02896335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Palbociclib and Pembrolizumab in Central Nervous System Metastases
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2017
Completion date
September 1, 2029
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm to brain, progressive brain metastases, recurrent brain metastases